[
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock underperforms Monday when compared to competitors",
    "summary": "Boston Scientific Corp. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9f2e9904cad91b80bd848bca84c071252741b7b436c6cf20f0c1ac2ddd090816",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741624560,
      "headline": "Boston Scientific Corp. stock underperforms Monday when compared to competitors",
      "id": 133152439,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9f2e9904cad91b80bd848bca84c071252741b7b436c6cf20f0c1ac2ddd090816"
    }
  },
  {
    "ts": null,
    "headline": "Positive Trial Data on Evolut TAVR Likely to Support MDT Stock",
    "summary": "At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.",
    "url": "https://finnhub.io/api/news?id=a53a15a960f0af370bc11d63c9b1dd5fda11443da255593d31b8fa3912707136",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610280,
      "headline": "Positive Trial Data on Evolut TAVR Likely to Support MDT Stock",
      "id": 133185390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.",
      "url": "https://finnhub.io/api/news?id=a53a15a960f0af370bc11d63c9b1dd5fda11443da255593d31b8fa3912707136"
    }
  },
  {
    "ts": null,
    "headline": "2 Reasons to Like BSX (and 1 Not So Much)",
    "summary": "Since March 2020, the S&P 500 has delivered a total return of 97.5%. But one standout stock has nearly doubled the market - over the past five years, Boston Scientific has surged 176% to $97 per share. Its momentum hasn’t stopped as it’s also gained 16.8% in the last six months thanks to its solid quarterly results, beating the S&P by 13%.",
    "url": "https://finnhub.io/api/news?id=10041d72875410c617c7af925c5bbffd6b1863cfa6a956b285c4e733d0a934d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741597725,
      "headline": "2 Reasons to Like BSX (and 1 Not So Much)",
      "id": 133185391,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Since March 2020, the S&P 500 has delivered a total return of 97.5%. But one standout stock has nearly doubled the market - over the past five years, Boston Scientific has surged 176% to $97 per share. Its momentum hasn’t stopped as it’s also gained 16.8% in the last six months thanks to its solid quarterly results, beating the S&P by 13%.",
      "url": "https://finnhub.io/api/news?id=10041d72875410c617c7af925c5bbffd6b1863cfa6a956b285c4e733d0a934d3"
    }
  }
]